Distribution of CT-DNA and viable CT at the vaginal and the rectal site at the follow-up visit (just prior to treatment) a median of 9 days later, in 560 women who were previously CT diagnosed (FemCure)
| Group A | Group B | Group C | Group D | |
| vCT and rCT | vCT (rCT untested) | vCT (rCT negative) | rCT (vCT negative) | |
| n=155, n (%) | n=351, n (%) | n=25, n (%) | n=29, n (%) | |
| CT-DNA (PCR positive) at follow-up | ||||
| No CT-DNA at vaginal and rectal site | 1 (0.6) | 19 (5.4) | 8 (32.0) | 8 (27.6) |
| CT-DNA detected at the vaginal site only | 20 (12.9) | 60 (17.1) | 8 (32.0) | 0 (0) |
| CT-DNA detected at the rectal site only | 2 (1.3) | 2 (0.6)* | 0 (0) | 21 (72.4) |
| CT-DNA detected at the vaginal and rectal site | 132 (85.2) | 270 (76.9)* | 9 (36.0)† | 0 (0) |
| Viable CT (PCR and V-PCR positive) at follow-up | ||||
| No CT-DNA or only non-viable CT at vaginal and rectal site | 6 (3.9) | 33 (9.4) | 13 (52.0) | 12 (41.4) |
| CT-DNA and viable CT at the vaginal site only | 48 (31.0) | 148 (42.2) | 10 (40.0) | 0 (0) |
| CT-DNA and viable CT at the rectal site only | 4 (2.6) | 6 (1.7)* | 0 (0) | 17 (58.6) |
| CT-DNA and viable CT at the vaginal and rectal site | 97 (62.6) | 164 (46.7)* | 2 (8.0)† | 0 (0) |
CT-DNA is assessed with a quantitative PCR; viable CT is assessed with a viability PCR.
*The rectal site was initially not tested, thus could be positive or negative. The fact that at follow-up (just prior to treatment), some women rectally had CT-DNA or viable CT-DNA suggests that in those women the rectal site was initially positive (350/351 patients reported no anal sex in 2 weeks prior to treatment).
†The rectal site was initially tested CT-DNA negative. The fact that at follow-up (just prior to treatment), women rectally had CT-DNA or viable CT-DNA suggests that new infections may have occurred at the rectal site between diagnosis and treatment (6/9 patients reported no anal sex in the 2 weeks prior to treatment).
rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.